Shares of DexCom rose sharply in after-hours trading, climbing 10.0% after the company published its second-quarter 2026 results following the market close. The continuous glucose monitoring specialist reported adjusted earnings per share of $0.70, beating the analyst consensus of $0.61 by $0.09, and posted revenue of $1.31 billion versus the $1.29 billion estimate.
Profitability measures were a central focus of the release. Adjusted EBITDA for the quarter was $421.3 million, ahead of the $390.7 million anticipated by analysts, translating to a 32.2% adjusted EBITDA margin and a 7.8% upside to expectations. Operating margin expanded to 24.3% from 18.4% in the same period a year earlier, underscoring a notable improvement in operating leverage.
Non-GAAP gross margin also improved, rising to 64.1% in Q2 2026 from 60.1% in the second quarter of 2025. International revenue grew organically by 16% during the quarter, contributing to the topline expansion.
For the full year, management provided a revenue guide of $5.18 billion to $5.25 billion, which sits in line with analyst consensus of $5.22 billion. The company further highlighted that it has an active $1 billion share repurchase program in place.
Analyst sentiment heading into the results had been largely positive. Of 28 analysts covering the company, 23 recommended a "Strong Buy," and recent activity included UBS resuming coverage with a Buy rating and Truist increasing its price target to $87 in the days before the report.
The market backdrop during the regular session was relatively stable, indicating the after-hours rally was driven by DexCom-specific news rather than a broad market move. The S&P 500 edged up 0.1%, the Dow Jones Industrial Average added 0.1%, and the Nasdaq gained 0.6% in the regular session.
Taken together, the combination of an earnings beat, improving gross and operating margins, healthy organic international growth, and an ongoing buyback gave investors reason to bid the shares higher after hours. In the immediate after-market reaction, the stock moved to $82, approaching its 52-week high of $87, reinforcing the narrative of a company in the midst of a profitability improvement.
Bottom line - DexCom posted stronger-than-expected results across earnings, revenue and adjusted EBITDA while reporting meaningful margin expansion. The full-year revenue range was consistent with consensus, and the company continues to return capital via a $1 billion repurchase program. These factors combined to produce the double-digit after-hours gain.